Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome

Launched by BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY, DHAKA, BANGLADESH · Oct 5, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating the role of Vitamin D in preventing severe forms of dengue fever, specifically Dengue Haemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS). Dengue is a viral illness spread by mosquitoes that can become serious for some patients. The trial aims to see if taking Vitamin D can help reduce the risk of these severe complications. The study will involve around 120 adults aged 18 to 65 who have tested positive for dengue and have had a fever for three days or less. Participants will be divided into three groups: one group will receive standard care, while the other two groups will receive standard care along with different doses of Vitamin D.

Participants can expect to be closely monitored throughout the study, which will take place from September 2023 to August 2024. They will be asked to attend appointments where their health will be checked, and they may receive follow-up calls to ensure their well-being. The side effects of Vitamin D are generally mild, but participants will be informed about what to watch for. It's important to note that this trial is part of standard care and does not offer compensation. Overall, this study could provide valuable information that might help in managing dengue fever more effectively in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \>18 to 65 years.
• • 2. NS1 positive people.
• • 3. Fever ≥ 100.4°F (≥38°C) for 3days or less
• • 4. Typical sign symptoms of Dengue fever.
• Exclusion Criteria:
• • 1. \>72hours of fever.
• • 2. Critically ill patients.
• • 3. Pregnancy
• • 4. Known Vitamin D hypersensitivity
• • 5. High serum calcium level
• • 6. Hypoalbuminaemia
• • 7. Malignancy
• • 8. Known nephrolithiasis and severe renal impairment.